Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-30
2007-10-30
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
11106201
ABSTRACT:
It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin. Topical application of APM and/or derivative can reduce or alleviate the symptoms associated with irritation of the skin and/or mucous membranes caused by contact or inhalation of these oils or fumes from burning vegetation containing these oils.
REFERENCES:
patent: 3492131 (1970-01-01), Schlatter
patent: 4259318 (1981-03-01), Duhe et al.
patent: 4594239 (1986-06-01), Pluim, Jr.
patent: 4663151 (1987-05-01), Waali
patent: 4803047 (1989-02-01), Pluim, Jr.
patent: 4861584 (1989-08-01), Powell, Jr. et al.
patent: 5409908 (1995-04-01), Sanchez et al.
patent: 5443847 (1995-08-01), West
patent: 5643572 (1997-07-01), Byers et al.
patent: 5654334 (1997-08-01), Edmundson et al.
patent: 5747052 (1998-05-01), Mimikos et al.
patent: 5767109 (1998-06-01), Sanchez et al.
patent: 6436429 (2002-08-01), Peyman
patent: 6630191 (2003-10-01), Amino et al.
patent: WO97/00692 (1997-01-01), None
patent: WO 00/18418 (2000-04-01), None
Morrot (Brain and Language 79 (2) 309 20, 2001).
Ludbrook (Clinical and Experimental Pharmacology and Physiology 28 (5 6) 488 92, 2001).
Bryant (Pediatric Allergy and Immunology 9 (3) 108 15, 1998).
Bezeau (Journal of Clinical and Experimental Neuropsychology 23 (3) 399 406, 2001).
Bolton (Journal of Clinical Pharmacology 38 (5) 408 12, 1998).
Willenheimer (Progress in Cardiovascular Diseases 44 (3) 155 67, 2001).
Chung (Plastic and Reconstructive Surgery 109 (1) 1 6, 2002).
Atkinson (Chronobiology International 18 (6) 1041 53, 2001).
Marks, et al. 1987, “Oral hyposensitization to poison ivy and poison oak,” Arch Dermatol 123:476-478).
Epstein, W.L. 1989, “Topical prevention of poison ivy/oak dermatitis,” Arch Dermatol 125:499-501.
Marks, et al. 1995, “Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite,” J Am Acad Dermatol 33:212-216.
Gelber, et al. 1997, “Down-regulation of poison ivy/oak-induced contact sensitivity by treatment with a class II MHC binding peptide:hapten conjugate,” J Immunol 158:2425-2434.
Baldwin, et al. 1999, “Regulation of the contact sensitivity response to urushiol with anti-urushiol monoclonal antibody ALG 991,” Arch Dermatol Res 291:652-658).
Vidmar, D.A. and Iwane, M.K. 1999, “Assessment of the ability of the topical skin protectant (TSP) to protect against contact dermatitis to urushiol (Rhus) antigen,” Am J Contact Dermat 10:190-197.
Stibich, et al. 2000, “Cost-effective post-exposure prevention of poison ivy dermatitis,” Int J Dermatol 39:515-518.
Hansen Eugenia S.
Hemingway & Hansen LLP
Lukton David
Oklahoma Medical Research Foundation
LandOfFree
Inhibition of allergic contact dermatitis by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of allergic contact dermatitis by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of allergic contact dermatitis by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896924